Iovance Biotherapeutics Inc
IOVA1.750USD
-1.420-44.79%
Cierre 05/09, 16:00（ET）Cotizaciones retrasadas 15 min
534.19MCap. mercado
PérdidaP/E TTM
Más Datos de Iovance Biotherapeutics Inc Compañía
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Información de la empresa
Código de la empresaIOVA
Nombre de la empresaIovance Biotherapeutics Inc
Fecha de salida a bolsaJun 20, 2008
Fundada en2017
Director ejecutivoDr. Frederick G. Vogt, J.D., Ph.D.
Número de empleados838
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección825 Industrial Road
CiudadSAN CARLOS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94070
Teléfono16502607120
Sitio Webhttps://www.iovance.com/
Código de la empresaIOVA
Fecha de salida a bolsaJun 20, 2008
Fundada en2017
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 4 de may
Hora de actualización: dom., 4 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Estadísticas de accionistas
Accionista
Proporción
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Tipo
Accionista
Proporción
Investment Advisor
24.77%
Investment Advisor/Hedge Fund
21.77%
Private Equity
13.95%
Hedge Fund
8.74%
Venture Capital
8.50%
Research Firm
3.25%
Bank and Trust
0.70%
Pension Fund
0.54%
Individual Investor
0.31%
Other
17.47%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
658
278.41M
85.05%
-24.34M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
2022Q4
639
197.16M
124.92%
+7.22M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Quogue Capital L.L.C.
28.07M
8.56%
+5.00M
+21.68%
Feb 20, 2024
The Vanguard Group, Inc.
27.48M
8.38%
+210.50K
+0.77%
Dec 31, 2024
MHR Fund Management LLC
24.42M
7.45%
+420.00K
+1.75%
Dec 31, 2024
Perceptive Advisors LLC
22.11M
6.74%
-4.51M
-16.93%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.17M
6.15%
+1.46M
+7.80%
Dec 31, 2024
State Street Global Advisors (US)
12.25M
3.74%
-952.70K
-7.22%
Dec 31, 2024
Hood River Capital Management LLC
8.99M
2.74%
+846.94K
+10.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.56M
2%
-1.97M
-23.08%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.87M
1.79%
+222.43K
+3.94%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
5.83M
1.78%
-26.82K
-0.46%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
1.21%
WisdomTree BioRevolution Fund
0.76%
Virtus LifeSci Biotech Products ETF
0.69%
Range Cancer Immunotherapy ETF
0.6%
SPDR S&P Biotech ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.08%
Strive Small-Cap ETF
0.06%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción1.21%
WisdomTree BioRevolution Fund
Proporción0.76%
Virtus LifeSci Biotech Products ETF
Proporción0.69%
Range Cancer Immunotherapy ETF
Proporción0.6%
SPDR S&P Biotech ETF
Proporción0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.18%
ProShares Ultra Nasdaq Biotechnology
Proporción0.11%
Invesco Nasdaq Biotechnology ETF
Proporción0.11%
iShares Biotechnology ETF
Proporción0.08%
Strive Small-Cap ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos